Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Anochlesia

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Anochlesia in 1 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Research Excerpts

ExcerptRelevanceReference
"Therefore, the THC-induced catalepsy model may be useful for distinguishing between both classes of NMDA receptor antagonists."1.29Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. ( Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T; Yamamoto, I, 1994)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kinoshita, H1
Hasegawa, T1
Kameyama, T1
Yamamoto, I1
Nabeshima, T1

Other Studies

1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Anochlesia

ArticleYear
Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
    Neuroscience letters, 1994, Jun-06, Volume: 174, Issue:1

    Topics: 2-Amino-5-phosphonovalerate; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amantadine;

1994